Cell signaling news
Here we present recent news items specially selected from Nature, Nature Medicine, Nature Biotechnology and Nature Reviews Drug Discovery.
July 2010
2010:
July |
June |
May |
April |
March |
February |
January
Other years: 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009
News | News Features
News
Universities shun Europe's drug initiative
Intellectual-property rules push researchers away.
Nature News (13 July 2009)
| Full Text |
Journals step up plagiarism policing
Cut-and-paste culture tackled by CrossCheck software.
Nature News (05 July 2009)
| Full Text |
NIH may open access to clinical facility
Outside investigators could pay to use the Clinical Center's state-of-the-art resources.
Nature News (06 July 2009)
| Full Text |
Sequencing firms vie for diagnostics market, tiptoe round patents
Genome sequencing companies are moving into clinical diagnostics, with the number of deals soaring, despite an uncertain patent landscape.
Nature Biotechnology News (July 2009)
| Full Text |
Trial watch: A boost for GSK's first-in-class heart drug?
A new study suggests an association between coronary heart disease and the inflammatory enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2), which is the target for GlaxoSmithKline's (GSK's) anti-atherosclerotic drug that is in Phase III trials.
Nature Reviews Drug Discovery News (July 2010)
| Full Text |
Fresh from the Pipeline: Sipuleucel-T
In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.
Nature Reviews Drug Discovery News (July 2010)
| Full Text |
Stem-cell furore erupts
Data analysis ignites public row.
Nature News (29 June 2010)
| Full Text |
Strong medicine for French research
The medical-research adviser to France's president aims to shift power and money to universities.
Nature News (28 June 2010)
| Full Text |
UK research centre born amid cuts
£600-million science complex planned for centre of London.
Nature News (23 June 2010)
| Full Text |
Strange lesions after stem-cell therapy
Unproven treatment results in mysterious masses.
Nature News (22 June 2010)
| Full Text |
Excitement grows for potential revolution in hepatitis C virus treatment
Data from a late-stage trial of the most advanced of a new class of drugs targeting the hepatitis C virus protease fuel hopes for major improvements in treatment outcomes.
Nature Reviews Drug Discovery News (July 2010)
| Full Text |
News Features
Targeting tumour metabolism
Metabolism in cancer cells differs from that in normal cells, but it is only recently that opportunities to specifically target these differences to develop novel anticancer drugs are being revealed. Jim Schnabel investigates new collaborations to harness this potential.
Nature Reviews Drug Discovery News Feature (July 2010)
| Full Text |
|
